Supplemental Validation Submission deadline extended
This article was originally published in The Gray Sheet
Executive Summary
Reprocessors will have until Nov. 1 to file additional validation data, FDA announces. The agency explains that some reprocessors submitted "good, but inadequate" information, necessitating additional time to complete supplemental validation submission (SVS) reviews. FDA will post additional details regarding SVS reviews by Aug. 13. The agency last updated its reprocessor validation guidance in May (1"The Gray Sheet" May 31, 2004, In Brief)...
You may also be interested in...
Reprocessed single-use devices
FDA will allow 30 days for SUD reprocessors to respond to additional-information letters concerning 510(k) Supplemental Validation Submissions, but will not grant time extensions, according to 1revised guidance issued May 27. "Manufacturers should have this validation information readily available since the reprocessed device(s) are currently marketed and such data should have been developed and maintained" under QS requirements, FDA reasons. Original 510(k) applicants, by contrast, are allowed 90-day extensions to respond to AI letters (2"The Gray Sheet" May 24, 2004, p. 10). The reprocessor 510(k) data validation guidance supersedes a July 2003 document...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.